The two main microdosing protocols, what clinical studies found (including the null results), who it might help, and how to do it safely. Based on peer-reviewed research, not hype.
Microdosing has attracted more popular coverage than almost any other topic in psychedelic research — and also more noise. Claims range from modest productivity improvements to treating treatment-resistant depression. The research is younger and messier than the headlines suggest.
This article covers what microdosing actually means, the two main protocols people use, what the published clinical and observational literature shows (including the studies that found no effect — those matter too), and how to approach it if you're considering it. Everything here is sourced to published research.
A microdose is a sub-perceptual dose of a psychedelic — specifically, a dose low enough that you should not experience any meaningful psychedelic effect. No visuals, no altered sense of time, no dissociation. The intent is to sit well below the threshold for acute psychedelic experiences while potentially accessing subtler changes in mood, focus, or cognition.
For dried psilocybin mushrooms, this is generally defined as 0.05 to 0.3 grams — compared to a typical recreational dose of 2–3.5g. For psilocybin specifically, this corresponds to roughly 0.35mg to 2mg of pure psilocybin.
The key word is sub-perceptual. If you're feeling clearly altered — enhanced sensory perception, emotional amplification, visual disturbances — the dose is no longer a microdose in the clinical sense. This distinction matters because most of the research studies a specific dose range; anecdotal reports of doses up to 1g being called "microdosing" describe a different experience category entirely.
Developed by researcher James Fadiman, who surveyed hundreds of microdosers over several years and summarised the findings in The Psychedelic Explorer's Guide (2011):
The rationale is avoiding tolerance build-up. Psilocybin builds rapid tolerance — taking it on consecutive days significantly reduces the effect — so the 3-day spacing maintains responsiveness while creating regular dosing.
Fadiman's surveys found a wide range of self-reported outcomes, with mood improvement and creativity most commonly cited. These are observational data — no control group, strong expectancy effects possible — but they are the empirical foundation for how most people approach the protocol.
Proposed by mycologist Paul Stamets, this protocol combines psilocybin with Lion's Mane mushroom (Hericium erinaceus) and niacin (vitamin B3):
Stamets hypothesises that Lion's Mane (which has documented neurogenesis effects via Nerve Growth Factor stimulation — see Mori et al., 2009, Phytotherapy Research) combined with psilocybin may produce synergistic neuroplasticity effects, with niacin acting as a "flushable" delivery vehicle to drive compounds past the blood-brain barrier.
Important note: The neuroplasticity hypothesis for the Stamets Stack is not yet supported by clinical trial evidence. It is a plausible mechanism proposed by a credentialed researcher, but it remains a hypothesis. Lion's Mane's individual effects on human neurogenesis are modest and still being studied; the three-way combination has not been formally trialled. The stack is widely used but its claimed mechanism is not yet demonstrated in humans.
Here is where it gets important to read carefully rather than rely on headlines.
Szigeti et al. (2021), eLife — This is the largest self-blinded study on microdosing to date. Researchers developed a clever method: participants who were already planning to microdose were asked to blind themselves to their doses using a system of coded capsules. 191 people completed the trial. The study found small but measurable improvements in depression and anxiety scores in the microdosing group compared to the placebo group.
The important caveats: the study could not rule out expectancy effects (people who wanted microdosing to work and believed they were taking it, even if they couldn't be certain). Effect sizes were modest. It was observational — participants chose whether to microdose, they weren't randomised. But the safety profile was excellent, and the study provides the best available evidence that something real may be happening at the population level.
Anderson et al. (2019), Harm Reduction Journal — A large survey (n=1,116) found that people who microdosed reported improvement in focus, mood, and creativity, with low rates of adverse events. Again: survey data, strong selection effects, no control group. But the consistency of self-reported outcomes across large samples is a signal worth noting.
Szigeti et al. note: Even the positive self-blinded study above noted that the effect sizes were small enough that expectancy could account for some of the result. The honest reading of the evidence is "possibly beneficial, probably not harmful, with uncertain mechanism."
Marschall et al. (2022), Journal of Psychopharmacology — This double-blind placebo-controlled crossover study (DOI: 10.1177/02698811211050556) is the most rigorous microdosing trial published to date. It found that psilocybin microdosing did not outperform placebo on anxiety or depression endpoints. The study used 0.5g doses (within the accepted microdose range) in a controlled setting.
This study gets less coverage than the positive findings. It should get more. It doesn't mean microdosing doesn't work — it means the specific effect on anxiety and depression at these doses and in this population was not detectable above placebo in a controlled setting. The expectancy effect is a real phenomenon in psychedelic research, and this study is the primary evidence that it accounts for some of the positive reports.
The honest synthesis: The evidence for microdosing is promising but not conclusive. Observational studies and surveys suggest real-world users report benefit. The most controlled trial found no effect on the primary endpoints. We don't yet know how much of the benefit is pharmacological and how much is expectancy. This is genuinely unresolved in the literature.
The population in most microdosing research is healthy adults seeking mood and performance improvement. The evidence base is weakest for clinical applications (treating diagnosed depression or anxiety) because those trials are still ongoing.
Consider with caution if:
Timing and context: The Fadiman protocol surveys consistently found that people who microdosed during low-stakes, reflective periods reported better outcomes than those who microdosed in high-pressure work environments. The idea that microdosing produces reliable productivity enhancement in stressful contexts is more marketing than evidence. What the surveys show is more nuanced: improved mood and reduced emotional reactivity in contexts that allow for reflection.
For dried mushrooms, a microdose is most reliably achieved using pre-weighed capsules rather than eyeballing dried material. Variation in moisture content and density makes eyeballed dried weight unreliable at the sub-0.3g scale.
A starting point supported by both the Fadiman protocol surveys and clinical studies:
The shroomDOSAGE calculator includes a microdose tier — selecting "microdose" maps your body weight and strain to the appropriate sub-perceptual range and will flag strain-potency adjustments automatically.
Every clinical microdosing study and every serious practitioner recommends journaling. It is the only way to distinguish a real effect from expectancy, adapt your dosing, and notice any problematic patterns early.
A simple template: on dose days and the day after, note mood (1–10), energy (1–10), focus (1–10), any notable thoughts or events, and any unexpected effects. After 4–6 weeks, review the pattern. If you can't identify a consistent signal in your own data, the protocol may not be producing a meaningful effect for you.
Psilocybin builds tolerance rapidly — see our tolerance article for the mechanism. This is why all microdosing protocols include off days. Taking psilocybin daily would produce progressively diminishing effects.
Both the Fadiman and Stamets protocols are designed around this tolerance dynamic. Staying on a protocol for more than 6–8 weeks without a break is not well-studied; most practitioners recommend a pause of 2–4 weeks after an extended microdosing cycle to allow full receptor reset before resuming.
The honest summary: some people report meaningful improvement in mood and wellbeing from microdosing, the safety profile at these doses is excellent, and the most rigorous controlled trial found no detectable effect on anxiety or depression above placebo. These two things can both be true.
Microdosing is worth approaching as an experiment with careful self-observation rather than a validated treatment. Use a structured protocol, keep a journal, respect the off days, and set a defined evaluation period before deciding whether to continue.
Dosage guidance reflects ranges used in published observational and clinical studies. This is not medical advice. If you are on psychiatric medication or managing a mental health condition, consult a healthcare provider before microdosing.
About the author
D.Spora — Research Desk
Every article on shroomDOSAGE starts with primary sources — clinical trials, published assay data, peer-reviewed pharmacology. We translate the findings into plain English so you can understand what the science actually says, without needing a medical degree. Sources are cited inline. Nothing here constitutes medical advice.
Your cart is empty.
Browse the catalogue to add items.